The paclitaxel injection market has witnessed significant growth in the past few years owing to its increasing demand in cancer treatment. Paclitaxel is a mitotic inhibitor used in chemotherapy. It was discovered in the bark of the Pacific Yew tree. Paclitaxel works by blocking cellular division through interfering with the normal functioning of microtubules. When administered in cancer treatment, paclitaxel prevents dividing cancer cells from separating, which further leads to cell death. The drug has shown encouraging results in fighting various types of cancers such as breast cancer, ovarian cancer, lung cancer, and Acquired Immune Deficiency Syndrome (AIDS)-related Kaposi's sarcoma. With the rising prevalence of cancer and increasing reliance on chemotherapy regimens containing paclitaxel injection, the market is expected to grow steadily over the forecast period.
Market Dynamics:
The global paclitaxel injection market is driven by the rising incidence of breast cancer and ovarian cancer. As per the World Health Organization, breast cancer is the most common cancer among women, with over 2 million new cases annually across the globe. Moreover, paclitaxel is extensively used in treating breast cancer. Additionally, advancing technologies for increasing the efficacy of paclitaxel are further augmenting the market growth. However, the availability of alternative treatment drugs and certain side-effects associated with paclitaxel injection are restraining factors. The development of nano-carrier drug formulations to reduce toxicity and improve paclitaxel delivery holds significant opportunities for market players.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook